Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00094
|
|||||
| Drug Name |
Glibenclamide
|
|||||
| Synonyms |
1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; Abbenclamide; Adiab; Apo-Glibenclamide; Azuglucon; Bastiverit; Benclamin; Betanase; Betanese 5; Calabren; Cytagon; Daonil; Daonil (TN); Debtan; Dia-basan; Diabeta; Diabeta (TN); Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglucon (TN); Euglucon 5; Euglucon N; Euglykon; G 0639; GBN 5; Gen-Glybe; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Gliben-Puren N; Glibenbeta; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida; Glibenclamida [INN-Spanish]; Glibenclamide (JP15/INN); Glibenclamidum; Glibenclamidum [INN-Latin]; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Gluco-Tablimen; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glyburide (USP); Glyburide (micronized); Glyburide [USAN]; Glycolande; Glycomin; Glynase; Glynase (TN); HB 419; HB 420; HB-419; HB-420; HB419; HB420; Hemi-Daonil; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Med-Glionil; Melix; Micronase; Micronase (TN); Micronized glyburide; Miglucan; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Nadib; Neogluconin; Norglicem 5; Normoglucon; Novo-Glyburide; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Semi-Daonil (TN); Semi-Euglucon; Semi-Gliben-Puren N; Semi-daonil; Sugril; Suraben; Tiabet; U 26452; U-26452; UR 606; Yuglucon
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Diabetes [ICD11: 5A10-5A14] | Approved | [1] | |||
| Therapeutic Class |
Hypoglycemic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H28ClN3O5S
|
|||||
| Canonical SMILES |
COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
|
|||||
| InChI |
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
|
|||||
| InChIKey |
ZNNLBTZKUZBEKO-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 10238-21-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 494 | Topological Polar Surface Area | 122 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321542
, 10502519
, 11111219
, 11112597
, 11113353
, 11119957
, 11120445
, 11120933
, 11121416
, 11121896
, 11147040
, 11335656
, 11360895
, 11362485
, 11363144
, 11365047
, 11365706
, 11367609
, 11368268
, 11370241
, 11370242
, 11372372
, 11373210
, 11375035
, 11375771
, 11376430
, 11461867
, 11466344
, 11467464
, 11485567
, 11486267
, 11489632
, 11491142
, 11493013
, 11494064
, 14835352
, 17405062
, 22391414
, 24277838
, 24895097
, 26542333
, 3146598
, 5047958
, 7847402
, 7979403
, 8147024
, 8150168
, 8152216
, 855894
, 9234
|
|||||
| ChEBI ID |
ChEBI:5441
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [3] | ||
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OATP2B1 | Transporter Info | Km = 6.26 microM | Human embryonic kidney cells (HEK293)-OATP2B1 | [4] | |
| References | ||||||
| 1 | Glibenclamide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8. | |||||
| 3 | Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. | |||||
| 4 | Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.